Based on these observations, the European Medicines Agency has curtailed the application of palliative cetuximab and panitumumab therapies for the treatment of CRC depending on the KRAS wild-type status of the tumor tissue, regardless of whether the antibodies are applied in combination with conventional chemotherapy or as single agents. The gene discussed is KRAS; the disease is neoplasm.